In contrast, in combination with α-PD-L1 (75 mg/mouse), the immunotherapeutic impact of Fe-TBP was significantly enhanced, inducing more than 90% tumor regression in local and distant tumors and increasing tumor-specific T cells such as infiltrating CD4+ and CD8+ T cells. Here, CD4 is linked to neoplasm.